Do analysts rate BGM or EGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, BGM or EGRX?

Eagle Pharmaceuticals has higher revenue and earnings than BGM Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BGM Group $37.92M 0.72 -$19.94M N/A N/A Eagle Pharmaceuticals $257.55M 0.03 $35.64M $1.18 0.50

Is BGM or EGRX more profitable?

Company Net Margins Return on Equity Return on Assets BGM Group N/A N/A N/A Eagle Pharmaceuticals N/A N/A N/A

Do analysts rate EGRX or UPC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, EGRX or UPC?

Eagle Pharmaceuticals has higher revenue and earnings than Universe Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eagle Pharmaceuticals $257.55M 0.03 $35.64M $1.18 0.50 Universe Pharmaceuticals $17.86M 1.59 -$3.67M N/A N/A

Is EGRX or UPC more profitable?

Company Net Margins Return on Equity Return on Assets Eagle Pharmaceuticals N/A N/A N/A Universe Pharmaceuticals N/A N/A N/A

Do analysts prefer EGRX or PSTV?

Plus Therapeutics has a consensus price target of $56.40, indicating a potential upside of 1,432.61%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Plus Therapeutics is more favorable than Eagle Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Plus Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43

Do analysts prefer EGRX or OPTH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Optimi Health 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is EGRX or OPTH more profitable?

Company Net Margins Return on Equity Return on Assets Eagle Pharmaceuticals N/A N/A N/A Optimi Health N/A N/A N/A

Do analysts rate TAOX or EGRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Eagle Pharmaceuticals (EGRX) Competitors

$0.60 0.00 (0.00%)

As of 08/14/2026

Compare

EGRX vs. BGM, UPC, PSTV, OPTH, and TAOX

Should you buy Eagle Pharmaceuticals stock or one of its competitors? Eagle Pharmaceuticals's main competitors and comparable companies include BGM Group (BGM), Universe Pharmaceuticals (UPC), Plus Therapeutics (PSTV), Optimi Health (OPTH), and Synaptogenix (TAOX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Eagle Pharmaceuticals compare to BGM Group?

BGM Group (NASDAQ:BGM) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. 58.7% of BGM Group shares are owned by company insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Eagle Pharmaceuticals has higher revenue and earnings than BGM Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$37.92M	0.72	-$19.94M	N/A	N/A
Eagle Pharmaceuticals	$257.55M	0.03	$35.64M	$1.18	0.50

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
Eagle Pharmaceuticals	N/A	N/A	N/A

In the previous week, BGM Group had 1 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 1 mentions for BGM Group and 0 mentions for Eagle Pharmaceuticals. BGM Group's average media sentiment score of 1.89 beat Eagle Pharmaceuticals' score of 0.00 indicating that BGM Group is being referred to more favorably in the media.

Company	Overall Sentiment
BGM Group	Very Positive
Eagle Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

BGM Group has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

Summary

BGM Group beats Eagle Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to Universe Pharmaceuticals?

Eagle Pharmaceuticals (NASDAQ:EGRX) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

In the previous week, Universe Pharmaceuticals had 2 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 2 mentions for Universe Pharmaceuticals and 0 mentions for Eagle Pharmaceuticals. Universe Pharmaceuticals' average media sentiment score of 1.43 beat Eagle Pharmaceuticals' score of 0.00 indicating that Universe Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Eagle Pharmaceuticals	Neutral
Universe Pharmaceuticals	Positive

85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Eagle Pharmaceuticals has higher revenue and earnings than Universe Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eagle Pharmaceuticals	$257.55M	0.03	$35.64M	$1.18	0.50
Universe Pharmaceuticals	$17.86M	1.59	-$3.67M	N/A	N/A

Eagle Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Eagle Pharmaceuticals	N/A	N/A	N/A
Universe Pharmaceuticals	N/A	N/A	N/A

Summary

Universe Pharmaceuticals beats Eagle Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to Plus Therapeutics?

Eagle Pharmaceuticals (NASDAQ:EGRX) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Eagle Pharmaceuticals has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Eagle Pharmaceuticals' return on equity of 0.00% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eagle Pharmaceuticals	N/A	N/A	N/A
Plus Therapeutics	-230.24%	-198.48%	-73.13%

In the previous week, Plus Therapeutics had 4 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 4 mentions for Plus Therapeutics and 0 mentions for Eagle Pharmaceuticals. Eagle Pharmaceuticals' average media sentiment score of 0.00 beat Plus Therapeutics' score of -0.28 indicating that Eagle Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Eagle Pharmaceuticals	Neutral
Plus Therapeutics	Neutral

85.4% of Eagle Pharmaceuticals shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 28.9% of Eagle Pharmaceuticals shares are held by company insiders. Comparatively, 2.5% of Plus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Eagle Pharmaceuticals has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

Plus Therapeutics has a consensus price target of $56.40, indicating a potential upside of 1,432.61%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Plus Therapeutics is more favorable than Eagle Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Eagle Pharmaceuticals has higher revenue and earnings than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eagle Pharmaceuticals	$257.55M	0.03	$35.64M	$1.18	0.50
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A

Summary

Eagle Pharmaceuticals beats Plus Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to Optimi Health?

Eagle Pharmaceuticals (NASDAQ:EGRX) and Optimi Health (NASDAQ:OPTH) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

Eagle Pharmaceuticals has higher revenue and earnings than Optimi Health. Optimi Health is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eagle Pharmaceuticals	$257.55M	0.03	$35.64M	$1.18	0.50
Optimi Health	$290K	93.06	-$1.12M	-$0.36	N/A

In the previous week, Optimi Health had 8 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 8 mentions for Optimi Health and 0 mentions for Eagle Pharmaceuticals. Optimi Health's average media sentiment score of 0.50 beat Eagle Pharmaceuticals' score of 0.00 indicating that Optimi Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Eagle Pharmaceuticals	Neutral
Optimi Health	Positive

Company	Net Margins	Return on Equity	Return on Assets
Eagle Pharmaceuticals	N/A	N/A	N/A
Optimi Health	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Optimi Health	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 28.9% of Eagle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Eagle Pharmaceuticals beats Optimi Health on 6 of the 10 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to Synaptogenix?

Synaptogenix (NASDAQ:TAOX) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Eagle Pharmaceuticals has higher revenue and earnings than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	84.54	-$28.74M	-$13.28	N/A
Eagle Pharmaceuticals	$257.55M	0.03	$35.64M	$1.18	0.50

Synaptogenix has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market.

10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Synaptogenix had 2 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 2 mentions for Synaptogenix and 0 mentions for Eagle Pharmaceuticals. Synaptogenix's average media sentiment score of 1.63 beat Eagle Pharmaceuticals' score of 0.00 indicating that Synaptogenix is being referred to more favorably in the media.

Company	Overall Sentiment
Synaptogenix	Very Positive
Eagle Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Eagle Pharmaceuticals has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. Eagle Pharmaceuticals' return on equity of 0.00% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	-2,153.97%	-128.51%	-97.54%
Eagle Pharmaceuticals	N/A	N/A	N/A

Summary

Eagle Pharmaceuticals beats Synaptogenix on 9 of the 14 factors compared between the two stocks.

Get Eagle Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EGRX vs. The Competition

Export

Metric	Eagle Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.73M	$11.88B	$7.02B	$13.06B
Dividend Yield	N/A	2.69%	2.56%	10.43%
P/E Ratio	0.50	782.06	271.65	25.45
Price / Sales	0.03	752.71	604.23	98.25
Price / Cash	0.40	15.03	28.87	38.47
Price / Book	N/A	10.36	11.07	6.51
Net Income	$35.64M	$2.79B	$3.45B	$347.33M
7 Day Performance	N/A	0.32%	0.96%	1.82%
1 Month Performance	N/A	0.19%	2.33%	3.06%
1 Year Performance	N/A	145.94%	63.28%	21.49%

Eagle Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EGRX Eagle Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$7.73M	$257.55M	0.50	100
BGM BGM Group	0.9233 of 5 stars	$0.31 +5.3%	N/A	-96.2%	$29.80M	$37.92M	N/A	298	Positive News Gap Down
UPC Universe Pharmaceuticals	1.371 of 5 stars	$5.81 -2.2%	N/A	+60.5%	$29.19M	$17.74M	N/A	220	Positive News Short Interest Decrease
PSTV Plus Therapeutics	2.0576 of 5 stars	$3.83 -0.3%	$56.40 +1,372.6%	-76.6%	$26.37M	N/A	N/A	20	Earnings Report Gap Down
OPTH Optimi Health	1.5367 of 5 stars	$4.60 -1.7%	N/A	N/A	$26.34M	$231.86K	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EGRX) was last updated on 8/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eagle Pharmaceuticals (EGRX) Competitors

EGRX vs. BGM, UPC, PSTV, OPTH, and TAOX

How does Eagle Pharmaceuticals compare to BGM Group?

Summary

How does Eagle Pharmaceuticals compare to Universe Pharmaceuticals?

Summary

How does Eagle Pharmaceuticals compare to Plus Therapeutics?

Summary

How does Eagle Pharmaceuticals compare to Optimi Health?

Summary

How does Eagle Pharmaceuticals compare to Synaptogenix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX vs. The Competition

Eagle Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eagle Pharmaceuticals (EGRX) Competitors

EGRX vs. BGM, UPC, PSTV, OPTH, and TAOX

How does Eagle Pharmaceuticals compare to BGM Group?

Do insiders & institutionals hold more shares of BGM or EGRX?

Which has preferable valuation and earnings, BGM or EGRX?

Is BGM or EGRX more profitable?

Does the media favor BGM or EGRX?

Do analysts rate BGM or EGRX?

Which has more volatility & risk, BGM or EGRX?

Summary

How does Eagle Pharmaceuticals compare to Universe Pharmaceuticals?

Does the media refer more to EGRX or UPC?

Do institutionals & insiders hold more shares of EGRX or UPC?

Which has better valuation & earnings, EGRX or UPC?

Which has more risk & volatility, EGRX or UPC?

Do analysts rate EGRX or UPC?

Is EGRX or UPC more profitable?

Summary

How does Eagle Pharmaceuticals compare to Plus Therapeutics?

Is EGRX or PSTV more profitable?

Does the media refer more to EGRX or PSTV?

Do insiders and institutionals believe in EGRX or PSTV?

Which has more risk & volatility, EGRX or PSTV?

Do analysts prefer EGRX or PSTV?

Which has better earnings and valuation, EGRX or PSTV?

Summary

How does Eagle Pharmaceuticals compare to Optimi Health?

Which has higher valuation and earnings, EGRX or OPTH?

Does the media prefer EGRX or OPTH?

Is EGRX or OPTH more profitable?

Do analysts prefer EGRX or OPTH?

Do institutionals & insiders believe in EGRX or OPTH?

Summary

How does Eagle Pharmaceuticals compare to Synaptogenix?

Which has stronger valuation and earnings, TAOX or EGRX?

Which has more risk & volatility, TAOX or EGRX?

Do insiders and institutionals hold more shares of TAOX or EGRX?

Does the media prefer TAOX or EGRX?

Do analysts rate TAOX or EGRX?

Is TAOX or EGRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX vs. The Competition

Eagle Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools